TYK2 and psoriasis: Extensive molecular profiling of 267 psoriasis patients undergoing deucravacitinib revealed that TYK2 inhibition restores the epidermal expression of pathologic hallmarks of psoriasis, such as K16, CD3, and Ki-67+ cells after 3 months of treatment [100].